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Background: There is currently a paucity of data regarding the clinical outcome of the everolimus-eluting stent (EES) in unselected patients with 
the whole spectrum of obstructive coronary artery disease as compared to the paclitaxel-eluting stent (PES) and the sirolimus-eluting stent (SES).
Methods: The study cohort comprised 6,615 consecutive patients who underwent coronary artery stent implantation with the EES (519), the 
PES (2,036) or the SES (4,060) at Washington Hospital Center. Patients who received bare metal stents, the zotarolimus-eluting stent, or two 
different types of drug-eluting stents were excluded. The clinical endpoints included death, death or Q-wave myocardial infarction (MI), target lesion 
revascularization (TLR), target vessel revascularization (TVR), definite stent thrombosis (ST) and major adverse cardiac events (MACE), defined as the 
composite of death, Q-wave MI, or TLR at 1 year.
Results: The groups were well matched for the conventional risk factors for coronary artery disease, except for hypertension, which differed among 
the three groups. The unadjusted endpoints for the EES and PES were death (4.5% vs. 7.1%; p=0.03), TLR (3.4% vs. 4.6%; p=0.24), TVR (5.6% vs. 
.1%; p=0.46), death or Q-wave MI (4.5% vs. 7.4%; p=0.02) and definite ST (0.0% vs. 0.7%; p=0.09). The unadjusted endpoints for the EES and SES 
were death (4.5% vs. 5.2%; p=0.45), TLR (3.4% vs. 5.8%; p=0.3), TVR (5.6% vs. 8.6%; p=0.05), death or Q-wave MI (4.5% vs. 5.4%; p=0.39) and 
definite ST (0.0% vs. 1.08%; p=0.003). The rates of MACE were similar among the three groups. Following multivariate analysis, the rate of death or 
Q-wave MI between the EES and PES groups was no longer significant (HR=1.14; 95% CI=0.59-2.20; p=0.70).
Conclusions: This study suggests that the use of EES in routine clinical practice is both safe and effective but offers no advantage in terms of hard 
endpoints over the PES or the SES.
